Ask what a drug for an enlarged prostate is supposed to do, and there are two honest answers that often get blurred into one. Alpha-blockers relax muscle in the prostate and bladder neck and ease urinary symptoms within days to weeks, but they leave the gland the same size and do little to change where the disease is heading. 5-alpha-reductase inhibitors work the other way: they act slowly over months, physically shrink an enlarged gland, and reduce the risk of acute urinary retention and surgery, mainly in men whose prostates are genuinely large. Combining the two beats either alone at preventing progression, again mostly in bigger glands, and none of it settles the separate matter of prostate-cancer screening.
Key points#
- The two main drug classes solve different problems: fast symptom relief versus slower disease modification.
- Alpha-blockers relax smooth muscle and improve flow quickly but do not shrink the gland or reliably prevent retention or surgery.
- 5-alpha-reductase inhibitors shrink the prostate over 6 to 12 months and lower the risk of retention and surgery, concentrated in larger glands.
- Combination therapy outperforms either drug alone on progression, and the guideline reserves it for men with demonstrable enlargement.
- These drugs are not a prostate-cancer screen, and finasteride or dutasteride roughly halve the PSA value, which must be accounted for.
The gland and the muscle: two sources of one complaint#
The urinary trouble men attribute to benign prostatic hyperplasia (BPH) comes from two mechanical sources sitting on top of each other. One is dynamic: the smooth-muscle tone of the prostate and bladder neck squeezing the channel that urine passes through. The other is static: the sheer bulk of an enlarged gland pressing inward. A useful picture is a garden hose running through a clamp. You can loosen the clamp, or you can thin the hose wall so there is more room inside. Loosening happens in minutes; thinning the wall takes time. The two drug classes map cleanly onto these two levers, which is why their trial signatures look so different.
Alpha-blockers: quick relief, unchanged biology#
Tamsulosin, alfuzosin, silodosin, doxazosin, and terazosin relax the muscular component. Symptom scores and urinary flow improve early, often within the first weeks, and the American Urological Association lists them as a standard option for bothersome moderate to severe symptoms. What they do not do is alter the gland itself. In the Medical Therapy of Prostatic Symptoms (MTOPS) trial, doxazosin lowered symptom scores and delayed overall progression, but that progression benefit was driven largely by symptom worsening rather than by the harder events. Doxazosin alone did not significantly reduce acute urinary retention or the need for surgery. Read plainly: the relief is real and fast, and the effect on the disease course is limited.
5-alpha-reductase inhibitors: slow, gland-shrinking, course-changing#
Finasteride and dutasteride block conversion of testosterone to dihydrotestosterone, the hormone that drives prostate growth. Over 6 to 12 months they trim prostate volume by roughly a fifth to a quarter. Their symptom benefit is more modest than an alpha-blocker's and is concentrated in men with larger glands, which is exactly what the hose analogy predicts, because thinning the wall only helps when a thick wall was the problem. Their distinctive value shows up on hard outcomes: in MTOPS, finasteride's benefit on clinical progression was concentrated in men with larger prostates rather than smaller ones, matching the biology directly.
What combination therapy actually demonstrated#
Two large randomized trials put the classes together, and both point the same direction.
MTOPS followed 3,047 men for a mean of about 4.5 years. Each monotherapy reduced the risk of overall clinical progression versus placebo, and combination therapy reduced it more than either drug alone. Finasteride and the combination, but not doxazosin by itself, lowered the long-term risk of acute urinary retention and invasive surgery.
The CombAT trial (short for Combination of Avodart and Tamsulosin) randomized 4,844 men with prostates of at least 30 mL and followed them four years. Combination therapy beat both monotherapies for symptom improvement and for reducing clinical progression, and it cut the relative risk of acute urinary retention or BPH-related surgery by about two thirds compared with tamsulosin. The combination was not superior to dutasteride alone for that retention-and-surgery endpoint, a reminder that most of the disease-modifying work came from the reductase inhibitor, not the alpha-blocker riding alongside it.
The shared message is not that more drugs are better for everyone. It is that combination therapy earns its keep in men with a demonstrably larger gland, not in every man with symptoms. The guideline reflects this by reserving combination therapy for evidence of enlargement, such as a volume above roughly 30 mL, an elevated PSA, or a prostate that is palpably big.
Judging each drug by the right endpoint#
Almost every misunderstanding here traces back to comparing these medicines on the wrong yardstick. A symptom score like the International Prostate Symptom Score is patient-reported and sensitive to expectation, so it responds well to placebo and to anything that relaxes muscle. The hard endpoints, acute urinary retention and surgery, track the disease course itself. A therapy can move symptom scores without preventing retention, and another can lower retention risk while nudging symptoms only a little. Grade an alpha-blocker by retention prevented and it looks weak; grade a reductase inhibitor by how fast it works and it looks slow. Neither judgment is fair, because each drug is being tested against a goal it was never built to reach. Matching the medicine to the outcome the patient actually cares about, whether that is feeling better next week or staying out of the operating room next decade, is the whole skill. Real choices depend on gland size, symptom severity, and individual risk.
Why none of this is prostate-cancer screening#
Benign enlargement and prostate cancer are separate conditions, and treating one tells you little about the other. One practical overlap matters at the bedside. Reductase inhibitors lower serum PSA by roughly half after 6 to 12 months, so a PSA drawn in a man taking finasteride or dutasteride generally needs to be doubled before it is read against normal ranges, or a genuine rise can be missed. Chemoprevention trials of these drugs found fewer prostate cancers overall but a signal of more high-grade tumors, and regulators did not approve them to prevent prostate cancer. Using a reductase inhibitor to shrink the gland and ease symptoms is therefore neither a cancer screen nor a prevention strategy, and any decision about PSA testing belongs in its own conversation.
Sources and further reading
Questions and answers
How soon should each drug start working?
An alpha-blocker usually eases symptoms within days to a few weeks. A 5-alpha-reductase inhibitor works on a longer clock, needing several months to shrink the gland before its symptom and progression benefits show, which is why patience is part of the prescription.
Does every man with prostate symptoms need combination therapy?
No. The trials show the added benefit of combining the two classes falls mainly on men with a larger prostate. For a man with bothersome symptoms but a modestly sized gland, an alpha-blocker alone is often the more sensible starting point, and guidelines reserve combination therapy for demonstrable enlargement.
If I take finasteride, can I still rely on my PSA?
You can, as long as the number is interpreted correctly. After 6 to 12 months on a reductase inhibitor, PSA runs about half its untreated value, so the result is typically doubled before comparison, and any real upward trend still deserves attention.